Painful Diabetic Peripheral Neuropathy – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Painful Diabetic Peripheral Neuropathy characteristically presents with a tingling sensation, numbness, burning, excruciating stabbing type of pain, sometimes intractable and may be associated with paraesthesia and hyperesthesia coupled with deep aching in feet or hands. Poor glycaemic control is a major risk factor for the development of diabetic neuropathy. It has been observed that an estimated 50% of patients develop Painful Diabetic Peripheral Neuropathy 25 years after the initial diagnosis of diabetes mellitus. The prevalence of PDN ranges from 10% to 20% of patients with diabetes and in those with diabetic neuropathy it ranges from 40% to 50%. The underlying mechanism for the generation of pain is hyperexcitability in primary afferent nociceptors, which occurs due to damage to peripheral nerves. This in turn leads to hyperexcitability in central neurons and the generation of spontaneous impulses within the axon as well as the dorsal root ganglion of these peripheral nerves.

In the ~26% to 52% of diabetic patients develop Painful Diabetic Peripheral Neuropathy, Prevalence results included both painful and nonpainful diabetic peripheral neuropathy.

The competitive landscape of Painful Diabetic Peripheral Neuropathy includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Painful Diabetic Peripheral Neuropathy across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Painful Diabetic Peripheral Neuropathy  Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Painful Diabetic Peripheral Neuropathy  – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          diepalrestat choline        NeuromaxBionevia        Phase 3

2          pregabalin         Pfizer    Phase 3

3          Engensis           Helixmith Co., Ltd.         Phase 3

4          ricolinostat        Regenacy Pharmaceuticals LLC Phase 2

5          NYX-2925         Aptinyx Phase 2

6          Mirogabalin       Daiichi Sankyo Co., Ltd. Phase 3

7          MT-8554           Mitsubishi Tanabe Pharma Corporation  Phase 2

8          PDA-002           Celularity Incorporated  Phase 2

9          ETX-018810      Eliem Therapeutics (UK) Ltd.     Phase 2

10        LX9211 Lexicon Pharmaceuticals           Phase 2 

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more